Table 9 Thyroid cancer and melanoma
From: Role of maspin in cancer
Authors | Years | N. patients | Maspin expression | Clinical features/prognosis/predictive factors |
|---|---|---|---|---|
Boltze et al. | 2004 | 68 (papillary carcinomas) | 70.5% positive maspin | Positive maspin in papillary cancer = 2% p53+, 83% 110 months OS, Recurrence free disease: 60 months |
38 (follicular carcinomas) | 100% negative maspin | Negative maspin in follicular carcinomas = 80%p53+, 40% 110 months OS, Recurrence free disease :40months | ||
Tahany et al. | 2006 | 63(thyroid specimes)= | 28.5%positive maspin | Positive maspin = 72% papillary thyroid, 61,1% positive cytoplasm and positive nucleus, 11.1 % positive nucleus and 27.8% positive cytoplasm, |
25 papillary carcinoma | 71.5% negative maspin | |||
Wada et al. | 2004 | 45 (malignant melanoma) | 12.5% positive maspin | |
87.5% negative maspin | Negative maspin in melanoma = 83% trunk, 89% extremites, 89% acral, 86% lentigo maligna melanoma, 100% nodular melanoma, 75% superficial spreading, 100% thickness 1.0-4.0 and >4 mm, 100% II-III-IV stage | |||
Chua et al. | 2009 | 77(malignant melanoma) | 59.7% positive maspin | Positive maspin = less microvessel density, 78% thin melanoma, 46% thick melanoma |
35.1% negative maspin | Negative maspin = high microvessel density, 22% thin melanomas, 54% thick melanoma |